Fintel reports that on March 7, 2025, Leerink Partners initiated coverage of CorMedix (NasdaqGM:CRMD) with a Outperform ...

We feel now is a pretty good time to analyse CorMedix Inc.'s ( NASDAQ:CRMD ) business as it appears the company may be... BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc ...

Shares of CorMedix Inc. (NASDAQ:CRMD – Get Free Report) have been assigned an average recommendation of “Buy” from the eight research firms that are covering the firm, Ratings reports. Seven analysts ...

Stock analysts at Leerink Partners started coverage on shares of CorMedix (NASDAQ:CRMD – Get Free Report) in a report ...

Leerink analyst Roanna Ruiz initiated coverage of CorMedix (CRMD) with an Outperform rating and $18 price target The firm believes the ...

Shares of CorMedix CRMD rose nearly 30% on Tuesday after management announced fourth-quarter and full-year 2024 preliminary sales figures. CorMedix reported preliminary net revenues of nearly $31 ...

Elliott Investment Management made several portfolio moves in the fourth quarter, closing multiple options positions and shaking up the activist firm's technology exposure. Shares of CorMedix ...

DefenCath, CorMedix's primary product, has been at the center of the company's recent success. The product, designed for use in outpatient settings, has shown promising signs since its launch. The ...

BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life ...

DefenCath, CorMedix's primary product, has been at the center of the company's recent success. The product, designed for use in outpatient settings, has shown promising signs since its launch.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and ...